Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Prevention of deep vein thrombosis.

BIBLIOGRAPHIC SOURCE(S)

  • Blondin MM. Prevention of deep vein thrombosis. Iowa City (IA): University of Iowa Gerontological Nursing Research Center, Research Dissemination Core; 2006 Feb. 40 p. [79 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Blondin M. Prevention of deep vein thrombosis. Iowa City (IA): University of Iowa Gerontological Nursing Research Center, Research Dissemination Core; 1999. 31 p.

** REGULATORY ALERT **

FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

  • February 28, 2008, Heparin Sodium Injection: The U.S. Food and Drug Administration (FDA) informed the public that Baxter Healthcare Corporation has voluntarily recalled all of their multi-dose and single-use vials of heparin sodium for injection and their heparin lock flush solutions. Alternate heparin manufacturers are expected to be able to increase heparin production sufficiently to supply the U.S. market. There have been reports of serious adverse events including allergic or hypersensitivity-type reactions, with symptoms of oral swelling, nausea, vomiting, sweating, shortness of breath, and cases of severe hypotension.
  • August 16, 2007, Coumadin (Warfarin): Updates to the labeling for Coumadin to include pharmacogenomics information to explain that people's genetic makeup may influence how they respond to the drug.

BRIEF SUMMARY CONTENT

 ** REGULATORY ALERT **
 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The grades of the strength and consistency of evidence (A1, A2, B1, B2, C1, C2, D) are defined at the end of the "Major Recommendations" field.

Definitions

Venous thrombi: "intravascular deposits composed predominantly of fibrin and red cells, with a variable platelet and leukocyte component". They often happen in the presence of stasis. These are commonly known as "blood clots."

Deep veins: This discussion is limited to the deep veins of the lower extremity. They include: posterior tibial, anterior tibial, peroneal, popliteal, femoral (common femoral, superficial femoral, profunda femoris), and iliac veins.

Pulmonary embolism: A thrombus that becomes mobile and travels to the pulmonary vasculature obstructing pulmonary circulation.

Anticoagulant: A substance that inhibits, prevents, or suppresses clotting of blood.

Individuals at Risk for Deep Vein Thrombosis

All surgical patients are considered at some degree of risk for development of deep vein thrombosis (DVT). This guideline focuses on the prevention of deep vein thrombosis in the elderly surgical patient. Advancing age is a known risk factor.

See Appendix A in the original guideline document for a comprehensive review of individuals at risk for the development of DVT and the effect of aging on DVT.

Assessment Criteria

Refer to the "Target Population" field of this summary for a listing of patients who are likely to benefit the most from use of this evidence-based guideline:

Description of Intervention

  1. Risk factor assessment should be completed for every patient upon admission to the hospital for all unplanned admissions (see "Thrombosis Risk Factor Assessment for Surgical and Medical Patients" in Appendix B of the original guideline document for an example).
  2. Risk factor assessment should be completed pre-operatively for every patient whose surgical admission is planned (Caprini et al., 1991. Evidence Grade = C1).
  3. Thorough education is provided for patient and family members regarding the importance of DVT prophylaxis and their role in assuring compliance. Provide written as well as verbal information regarding the basic physiology about how blood flows to and from the heart, and the role of muscles in this process. Empower patients to be active participants in exercise, ambulation (if not contraindicated), and in the use of mechanical devices (Blondin & Titler, 1996. Evidence Grade = D).
  4. Appropriate prophylaxis should be initiated as soon as medically possible for unplanned admissions (Hamilton, Hull, & Pineo, 1994. Evidence Grade = A1).
  5. Appropriate prophylaxis should be initiated preoperatively for planned same-day admissions or on admission to the inpatient unit for those patients admitted on any day preceding their scheduled surgery (Hamilton, Hull, & Pineo, 1994. Evidence Grade = A1).
  6. Patients arriving to nursing units without orders for DVT prophylaxis: nursing staff should immediately notify responsible physician.
  7. All patients should have a plan for active and passive lower extremity activity unless contraindicated including flexion and extension of the ankle (ankle pumps), knees and hips. Involve Physical Therapy as appropriate. Provide written instructions, with pictures as well as a demonstration.
  8. Early and aggressive ambulation for all patients if not contraindicated by condition.
  9. If the following regimens are ordered, follow these guidelines:
    1. Graduated Compression Stockings (GCS): wear at all times except when removed for skin care or bathing. Replace within 30 minutes (Sigel et al., 1975).
      • Measure each patient; do not "guess" size.
      • Consider knee high GCS for patients unable to wear thigh high due to size, injury, or physician preference.
      • Avoid stockings that threaten a "garter" effect at the calf, posterior knee or thigh.
      • Re-measure postoperatively for patients undergoing lower extremity surgery.
      • Note manufacturer's list of "contraindications for use" accompanying product prior to applying.
    1. Intermittent Pneumatic Compression Devices (IPCD): wear at all times when inactive. This includes when patient is in bed, resting in the chair, or at lengthy tests.
      • Measure each patient; do not "guess" size.
      • Consider knee high IPCD for patients unable to wear thigh high due to size, injury, or physician preference.
      • Note manufacturer's list of "contraindications for use" accompanying product prior to applying.
    1. Foot Pumps: wear at all times when inactive. This includes when patient is in bed, resting in the chair, or at lengthy tests.
      • Note manufacturer's list of "contraindications for use" accompanying product prior to applying.
    1. Anticoagulant Therapy per physician order.
    2. Continue GCS use after discharge for period of relative immobility (Caprini, Scurr, & Hasty, 1988; Clagett & Reisch, 1988. Evidence Grade = A1). This definition is variable and needs to be determined at your institution. A good rule of thumb is "up more than down". Hamilton, Hull, & Pineo, (1994) defined this as ambulating three to four hours per day (Evidence Grade = A1).
    3. Continue anticoagulant therapy after discharge per Licensed Independent Practitioner (LIP) order.
  1. Monitor for clinical signs and symptoms of DVT (50% confidence) such as calf pain or tenderness, palpable cords, increased circumference, positive Homan's sign (Hamilton, Hull, & Pineo, 1994. Evidence Grade = A1).

Definitions:

Evidence Grading

A1 = Evidence from well-designed meta-analysis or well-done systematic review with results that consistently support a specific action (e.g. assessment, intervention, or treatment)

A2 = Evidence from one or more randomized controlled trials with consistent results

B1 = Evidence from high quality evidence-based practice guideline

B2 = Evidence from one or more quasi experimental studies with consistent results

C1 = Evidence from observational studies with consistent results (e.g. correlational, descriptive studies)

C2 = Inconsistent evidence from observational studies or controlled trials

D = Evidence from expert opinion, multiple case reports, or national consensus reports

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

REFERENCES SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for selected recommendations (see "Major Recommendations" field).

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Blondin MM. Prevention of deep vein thrombosis. Iowa City (IA): University of Iowa Gerontological Nursing Research Center, Research Dissemination Core; 2006 Feb. 40 p. [79 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1999 Jun 10 (revised 2006 Feb)

GUIDELINE DEVELOPER(S)

University of Iowa Gerontological Nursing Interventions Research Center, Research Translation and Dissemination Core - Academic Institution

SOURCE(S) OF FUNDING

Developed with the support provided by Grant #P30 NR03979, [PI: Toni Tripp-Reimer, The University of Iowa College of Nursing], National Institute of Nursing Research, NIH

GUIDELINE COMMITTEE

University of Iowa Gerontological Nursing Interventions Research Center Research Dissemination Core

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Author: Martha Blondin, RN, MSN
Series Editor: Marita G. Titler, PhD, RN, FAAN

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Blondin M. Prevention of deep vein thrombosis. Iowa City (IA): University of Iowa Gerontological Nursing Research Center, Research Dissemination Core; 1999. 31 p.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on November 19, 1999. The information was verified by the guideline developer as of January 20, 2000. This NGC summary was updated by ECRI on June 13, 2006. The updated information was verified by the guideline developer on June 27, 2006. This summary was updated by ECRI on March 6, 2007 following the U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin sodium). This summary was updated by ECRI Institute on June 22, 2007 following the U.S. Food and Drug Administration (FDA) advisory on heparin sodium injection. This summary was updated by ECRI Institute on September 7, 2007 following the revised U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin). This summary was updated by ECRI Institute on March 14, 2008 following the updated FDA advisory on heparin sodium injection.

COPYRIGHT STATEMENT

This summary is based on content contained in the original guideline, which is subject to terms as specified by the guideline developer. These summaries may be downloaded from the NGC Web site and/or transferred to an electronic storage and retrieval system solely for the personal use of the individual downloading and transferring the material. Permission for all other uses must be obtained from the guideline developer by contacting the University of Iowa Gerontological Nursing Intervention Research Core.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo